ArticleMolecular biology reports2026
Combined metformin and Taurine attenuate age-related bone loss.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAge-related bone loss is closely associated with functional decline and exhaustion of bone marrow mesenchymal stem cells (BMSCs). This study aimed to investigate whether combined Metformin and Taurine (Met + Ta) treatment could attenuate aging-associated skeletal deterioration and preserve BMSC function.
methodsEighteen-month-old male C57BL/6J mice were treated with Met, Ta, or Met + Ta for 8 consecutive weeks. Bone microarchitecture was evaluated by micro-computed tomography and histological staining. BMSCs were isolated from aged mice and assessed for osteogenic differentiation, proliferative capacity, senescence-related changes, and inflammatory cytokine production. Transcriptomic analysis was performed to identify molecular changes associated with Met + Ta treatment, and siRNA-mediated Crebrf knockdown was used for functional validation.
resultsMet + Ta treatment improved bone mass and trabecular microarchitecture more effectively than either single treatment. Histological staining further showed better preservation of trabecular structure and increased collagen-rich matrix deposition in the Met + Ta group. BMSCs from Met + Ta-treated mice exhibited enhanced osteogenic differentiation, increased proliferative activity, reduced senescence-associated phenotypes, and improved inflammatory homeostasis. Transcriptomic analysis revealed coordinated regulation of genes involved in proliferation, senescence, metabolism, proteostasis, and genome maintenance. Crebrf was identified as a candidate regulatory mediator, and Crebrf knockdown attenuated the anti-senescent and cellular-stability-related effects of Met + Ta in BMSCs.
conclusionsCombined Met and Ta treatment alleviates age-related bone loss and preserves BMSC function more effectively than single-agent treatment. These findings suggest that Met + Ta may represent a potential combined strategy for delaying skeletal aging, with Crebrf serving as a candidate mediator of its protective effects.
Indexed as
Identifiers
42364025What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.